ПРОТИВООПУХОЛЕВЫЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА

Обзор посвящен вопросам, связанным с особенностями разработки и клинического применения биотехнологических препаратов, действующим веществом которых являются моноклональные антитела, и препаратов на основе модифицированных моноклональных антител. В обзоре приведены современные представления, касающиеся механизмов канцерогенеза, поддержания злокачественного фенотипа опухолевых клеток, неконтролируемого роста опухолей, приспособительной способности опухолей для уклонения от противоопухолевого иммунитета организма. Отражены особенности механизма специфического биологического действия препаратов моноклональных антител, лежащих в основе их терапевтического воздействия при клиническом применении. Приведены общие принципы и возможные перспективы разработки указанных препаратов с иммунотропной направленностью действия для таргентной терапии за счёт воздействия на конкретные молекулы, участвующие в механизмах канцерогенеза и роста опухолей.

Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 2000; 100 (1): 57-70.

Green M.C., Murray J.L., Hortobagyi G.N. Monoclonal antibody therapy for solid tumors. Cancer Treat. Rev. 2000; 26 (4): 269-86.

Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480 (7378): 480-9.

Vannemann M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer. 2012; 12: 237-50.

Ciariello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Canc. Res. 2001; 7 (10): 2958-70.

Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 2006; 90: 1-50.

Zitvogel L., Tesniere A., Schreiber R.D., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006; 6 (10): 715-27.

Zou W. Immunosupressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer. 2005; 5: 263-74.

Garrido F., Cabrera T., Lopez-Nevot M.A., Ruiz-Cabello F. HLA class I antigens in human tumors. Adv. Cancer Res. 1995; 67: 155-95.

Momburg F., Ziegler A., Harpprecht J., Moller P., Molden- Hauer G., Hammerling G.J. Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J. Immunol. 1989; 142: 352-8.

O’Flaherty E., Wong W.K., Pettit S.J., Seymour K., Ali S., Kirby J.A. Regulation of T-cell apoptosis: a mixed lymphocyte reaction model. Immunology. 2000; 100 (3): 289-99.

Kinder M., Chislock E., Bussard K.M., Shuman L, Mastro AM. Metastatic breast cancer induces an osteoblast inflammatory response. Exp. Cell Res. 2008; 324 (1): 173-83.

Wright-Browne V., McClain K., Talpaz M., Ordonez N., Estrov Z. Physiology and pathophysiology of dendritic cells. Hum. Pathol. 1997; 28: 563-79.

Shurin M.R., Shruin G., Lokshin A., Yurkovetsky Z.R., Gutkin D.W., Chatta G. et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Met. Rev. 2006; 25 (3): 333-56.

Zhang L., Yeger H., Das B., Irwinz M.S., Baruchel S. Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma. Neoplasia. 2007; 9 (1): 36-46.

Andersen M.H. The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.Cancer Immunol. Immunother. 2012; 61: 1289-97.

Wesa A.K., Storkus W.J. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death. Different. 2008; 15: 51-7.

Jonson P., Glennie M. Rituximab: mechanisms and applications. Br. J. Cancer 2001; 85 (11): 1619-23.

Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer. 2001; 37 (4): 9-15.

Сакаева Д.Д., Гордиев М.Г. Рецептор эпидермального фактора роста как мишень молекулярно-направленной терапии у непредлеченных пациентов с немелкоклеточным раком легкого. Журнал «Злокачественные опухоли». 2016; 19 (3): 54-9

Abbruzzese J.L. Phase 2 study of anti-epidermal growth factor receptor (EGFR) antibody (IMC-C225), in combination with gemcitabine in patient with advanced pancreatic cancer. Ibid. 2001; 20: 518 (abstr).

Saltz Z., Rubin M. Cetuximab (IMC - C225) plus irinotecan (CPT - 11) is active in CPT-11 refractory colorectal cancer that express EGFR. Ibid. 2001; 20: 511 (abstr).

Hamilton A., Piccart M. The contribution of molecular markers to the prediction of response in the treatment of brest cancer: a review of the literature on Her-2, p53 and Bcl-2. Ann. Oncol. 2000; 11 (6): 647-63.

McKeage K., Perry C. Trastuzumab. A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002; 62 (1): 209-43.

Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L. et al: Efficacy and safety of Trastuzumab as a single agent in firstline treatment of HER2 overexpressing metastatic breast cancer (HER2+/MBC). J. Clin. Oncol. 2002; 3: 719-26.

Melnyk O., Zimmerman M., Kim K., Schuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J. Urol. 1999; 161: 960-3.

Neal D., Donovan J. Screening for prostate cancer. Ann. Oncol. 1998; 9: 12-7.

Bouzin C., Brouet A., De Vriese J., Dewever J., Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J. Immunol. 2007; 178 (3): 1505-11.

Huang Y., Chen X., Dikov M.M., Novitskiy S.V., Mosse C.A., Yang L., Carbone D.P. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood. 2007; 110 (2): 624-31.

Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab - VEGR. Drugs. 2002; 3 (1): 28-30.

Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R. et al. Randomized controlled trial of Yttrium-90-labelled Ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low grade, follicular or transformed B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 2002; 20 (10): 2453-63.

Chapman P.B., Hauschild A., Robert C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl. J. Medicine. 2011; 364 (26): 2507-16.

Menzies A.M., Long G.V., Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design Develop. Ther. 2012; 6: 391-405.

Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380 (9839): 358-65.

Haferkamp S., Borst A., Adam C., Becker T.M., Motschenbacher S., Windhovel S. et al. Vemurafenib induces senescence features in melanoma cells. J. Invest. Dermatol. 2013; 133: 1601-9.

Zhen L., Ke J., Xiaofang Zh., Guibin L., Fei S. Yongfu Zh. et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016; 370 (2): 332-44.

Novartis Pharmaceuticals, Study comparing combination of LGX818 plus MEK162 and LGX818 monotherapy versus vemurafenib in BRAF mutant melanoma (COLUMBUS). Clin. Trials. Gov. NCT01909453. 2015.

Lugowska I., Koseła-Paterczyk H., Kozak K., Rutkowski P. Trametinib: a MeK inhibitor for management of metastatic melanoma. OncoTarg. Ther. 2015; 8: 2251-9.

Larkin J., Ascierto P.A., Dréno B., Atkinson V., Liszkay G., Maio M. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 2014; 371 (20): 1867-76.

Pedoeem A., Azoulay-Alfaguter I., Strazza M., Silverman G.J., Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin. Immunol., 2014; 153 (1): 145-52.

Liang S.C., Latchman Y.E., Buhlmann J.E., Tomczak M.F., Horwitz B.H., Freeman G.J., Sharpe A.H. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 2003; 33 (10): 2706-16.

Chen D., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39 (1): 1-10.

Jurado J.O., Alvarez I.B., Pasquinelli V., Martínez G.J., Quiroga M.F., Abbate E. et al. Programmed death (PD)-1:PD-Ligand 1/PD-Ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J. Immunol. 2008; 181: 116-25.

Sharpe A.H., Wherry E.J., Ahmed R., Freeman G.J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunology. 2007; 8: 239-45.

Ishida M., Iwai Y., Tanaka Y., Okazaki T., Freeman G.J., Minato N., Honjo T. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 2002; 84 (1): 57-62.

Maine C.J. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Can. Immunol. Immunother. 2014; 63 (3): 215-24.

Mao Y., Li W., Chen K., Xie Y., Liu Q., Yao M. et al. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015; 6 (5): 3452-61.

Chen L., Zhang Z., Chen W., Zhang Z., Li Y., Shi M. et alB7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol. 2007; 178: 6634-41.

Merelli B, Massi D, Cattaneo L, Mandala M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit. Rev. Oncol. Hematol. 2014; 89 (1): 140-65.

Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012; 12: 252-64.

Chen D., Irving B., Hodi F. Molecular pathways: next-generation immunotherap-inhibiting. Clin. Cancer Res. 2012; 18: 6580-7.

Hanahan D., Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011; 144 (5): 646-74.

Nelson D., Fiaher S., Robinson B. The “Trojan Horse” approach to tumor immunotherapy: targeting the tumor microenvironment. J. Immunol. Res. 2014; 15: 308.

Quesada S., Peggs K. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br. J. Cancer. 2013; 108: 1560-5.

Choueiri T.K., Fay A.P., Gray K.P., Callea M., Ho T.H., Albiges L. et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann. Oncol. 2014; 25 (11): 2178-84.

Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008; 26: 677-704.

Liu C., Peng W., Xu C., Lou Y., Zhang M., Wargo J.A. et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 2013; 19: 393-403.

Pollack B.P., Sapkota B., Cartee T.V. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin. Cancer Res. 2011; 17: 4400-13.

Soria J.C. Stahel A. PD-1 inhibitors raise survival in NSCLC. Cancer Discov. 2014; 4 (1): 6.

Maio M., Grob J.J., Aamdal S., Bondarenko I., Robert C., Thomas L. et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol. 2015; 33 (10): 1191-6.

Нуриев Р.И., Караулов А.В., Киселевский М.В. Новые стратегии лечения пациентов с онкологическими заболеваниями: иммунотерапевтический подход. Иммунология. 2017; 38 (1): 39-48